FindTrial
Sign In

Identification of a suitable milk-derived product, the consumption of which could prevent vitamin B12 deficiency (IMPROVIT)

Uptake of various forms and amounts of vitamin B12 (Part I-IMPROVIT) - IMPROVIT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/01/007712
Enrollment
61
Registered
2017-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control Intervention1: hydroxocobalamin and cyanocobalmin in vitamin B12 deficient participants (less tha 148 pmol/L): oral three doses of hydroxocobalamin and cyanocobalmin (both 1.5, 3.0 and 6.0 ug
Day1: 3/6/9 microgram thrice a day Blood collection on day 0 and day 3

Sponsors

Department of Biotechnology New Delhi India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Vegetarians with low plasma vitamin B12 in Indian participants and with normal vitamin B12 status Danish participants

Exclusion criteria

Exclusion criteria: Non vegetarians, cancer and the participants consuming vitamin B12 pills and the drugs known to influence vitamin B12 absorption

Design outcomes

Primary

MeasureTime frame
Difference in uptakeTimepoint: Baseline and two days after supplementation and then crossover—

Secondary

MeasureTime frame
Metabolic effects of both cyano and hydroxo coabalamin in vegetarian IndiansTimepoint: Holotranscoabalamin levels before and after supplementation and crossover—

Countries

India

Contacts

Public ContactDr Sadanand S Naik

Pathology Department, Deenanath Mangeshkar Hospital and Research Center

sadu_naik@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026